Investors

Developing transformative therapies targeting cancer

Founded 20 years ago, Seattle Genetics was built on a foundation of scientific innovation, rigorous research and drug development practices, as well as a passion for helping patients. Our leadership in antibody-drug conjugates (ADCs) and focus on innovative, targeted therapies for cancer has resulted in an approved drug for multiple indications and a robust pipeline of innovative programs in clinical development for a range of hematologic and solid tumors.

Recent News
Seattle Genetics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares More
Seattle Genetics Announces Pricing of Public Offering of Common Stock More
Seattle Genetics Announces Proposed Public Offering of Common Stock More
Events


Copyright West LLC. Minimum 15 minutes delayed.